Anavex life sciences announces peer-reviewed publication of oral blarcamesine phase iib/iii data in the journal of prevention of alzheimer's disease

Blarcamesine potential novel oral treatment to target upstream alzheimer's disease pathology through autophagy enhancement

AVXL Ratings Summary

AVXL Quant Ranking